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PENILAIAN KEPATUHAN DOKTOR TERHADAP CADANGAN 
PENGUBATAN BAGI PENGURUSAN HIPERTENSI DI DALAM PANDUAN  





Literatur sedia ada menunjukkan salah satu faktor penyumbang utama kepada kawalan 
buruk hipertensi adalah akibat tidak kepatuhan doktor terhadap panduannya. 
Penyelidikan ini melibatkan kajian keratin lintang 26 orang doktor di Hospital Pulau 
Pinang (HPP). Matlamatnya ialah untuk menilai pengetahuan, sikap dan amalan para 
doktor terhadap panduan praktis klinikal hipertensi Malaysia CPG (2008) dan faktor-
faktor yang berkaitan kepatuhan panduan dan kawalan hipertensi. Pengetahuan dan 
sikap para doktor terhadap CPG (2008) telah dinilai menggunakan satu soal-selidik. 
Preskripsi yang ditulis oleh 26 orang doktor untuk 650 orang pesakit luar hipertensi (25 
preskripsi bagi setiap orang doktor dengan kadar terkeluar kajian 25%) bersama dengan 
data demografi dan klinikal pesakit telah diperolehi pada lawatan pertama. Preskripsi 
yang diperolehi dikelaskan kepada samada patuh atau tidak patuh terhadap CPG (2008). 
Seramai lima ratus dua puluh pesakit (50%) (20 orang pesakit bagi setiap orang doktor 
telah disusuli untuk satu kali lagi lawatan(kedua). SPSS versi 16 telah digunakan untuk 
menganalisa data. Satu nilai p <0.05 digunakan sebagai statistik yang sigifikan. Berdasar 
kepada kriteria kesedaran didapati 19 orang doctor (73.07%) mempunyai pengetahuan 
yang mencukupi  berkenaan CPG (2008). Kumpulan yang terdiri daripada pakar dan 
pakar perunding mempunyai pengetahuan CPG (2008) yang lebih baik daripada 
pegawai-pegawai perubatan (nilai p<0.001). Doktor bersikap positif terhadap CPG 
(2008) dengan mata skor purata 23.15+1.34 dan julat mata 19-24 diatas skala mata 30. 
Korelasi positif yang baik dan signifikan secara statistik  diantara pengetahuan doktor 
 xx 
dengan skor praktis telah diperolehi (rs=0.635, nilai p<0.001). Tiga ratus empat puluh 
sembilan pesakit (67.1%) telah menerima farmakoterapi yang komplian terhadap 
panduan. Analisa multivariat telah mendapati klinik hipertensi sebagai prediktor kuat 
terhadap ketidakpatuhan panduan (OR=0.398, nilai p=0.008). Pada lawatan kedua 
seramai dua ratus enem puluh lima pesakit (51.0%)telah mencapai matlamat BP. Analisa 
multivariat telah mendapati perencat  penukar enzim angiotensin (OR=2.100, nilai  
p=0.001) dan kepatuhan terhadap panduan (OR=1.745, nilai p=0.022)  sebagai prediktor 
kuat kawalan hipertensi sementara penyakit ginjal (OR=0.283, nilai p<0.001), diabetes 
mellitus (OR =0.598, nilai p=0.025) dan klinik diabetes (OR =0.384, nilai p=0.024) 
sebagai prediktor kuat  bagi kawalan buruk hipertensi. Kajian ini menunjukan 
pengetahuan doktor yang mencukupi, kepatuhan CPG (2008) memberikan kawalan baik 
hipertensi di HPP. Jurang perbezaan  diantara cadangan CPG (2008) dengan praktis 
klinikal telah dapat dilihat dengan jelas dalam farmakoterapi hipertensi yang tidak 





















EVALUATION OF DOCTORS’ ADHERENCE TO MEDICATION 
RECOMMENDATIONS OF CLINICAL PRACTICE GUIDELINES ON 






The existing literature suggests that doctors’ divergence from guidelines is one of the 
major contributing factors for poor control of hypertension. The present research in 
which 26 doctors were enrolled was cross sectional study conducted at Hospital Pulau 
Pinang (HPP). Its aim was to evaluate doctors’ knowledge, attitude and practice of 
Malaysian clinical practice guidelines on the management of hypertension CPG (2008), 
and factors associated with guidelines’ adherence and hypertension control. Doctors’ 
knowledge and attitudes on CPG (2008) were evaluated through a questionnaire. 
Prescriptions written by 26 enrolled doctors to 650 established hypertensive outpatients 
(25 prescriptions per enrolled doctor with 25% drop out rate) were noted on visit one 
along with patients’ demographic and clinical data. The noted prescriptions were 
classified either as adherent or non adherent to CPG (2008). Five hundred and twenty 
(80%) of the enrolled patients (20 patients per enrolled doctor) were followed for one 
more visit. Blood pressure (BP) noted on visit 2 was related to the prescription written 
on visit one. SPSS 16 was used for data analysis. A p-value <0.05 was considered 
statistically significant. Nineteen doctors (73.07%) had adequate knowledge of CPG 
(2008). Group composed of specialists and consultants had significantly better 
knowledge of CPG (2008) than medical officers (p-value <0.001). Doctors were highly 
positive towards CPG (2008) with mean attitude score of 23.15+1.34 points, ranging 
from 19-24 points on a 30 point scale. Statistically significant strong positive correlation 
 xxii 
(rs= 0.635, p-value 
 
<0.001) was observed between doctors’ knowledge and practice 
scores. Three hundred and forty nine (67.1%) patients received guidelines adherent 
therapy. In multivariate analysis hypertension clinic (OR=0.398, p-value =0.008) was 
the strong predictor of poor adherence with guidelines. On visit Two, 265 patients (51%) 
were at goal BP. In multivariate analysis, Angiotensin converting enzyme inhibitors 
(OR=2.100, p-value=0.001) and guidelines adherence (OR=1.745, p-value=0.022) were 
the strong predictors of hypertension control, while renal disease (OR=0.283, p-value 
<0.001), diabetes mellitus (OR =0.598, p-value =0.025) and diabetic clinic (OR =0.384, 
p-value =0.024) were the strong predictors of poor control of hypertension. An overall 
fair to good level of doctors’ knowledge, adherence to guidelines and control of 
hypertension was observed at HPP. The gaps between what CPG (2008) recommended 
and clinical practice was especially seen in the pharmacotherapy of uncomplicated 

















Hypertension is defined as persistently elevated systolic blood pressure (SBP) of 140 
mm Hg or greater and/or diastolic blood pressure (DBP) of 90 mm Hg or greater 
(Malaysian Hypertension Guideline Working Group, 2008). Hypertension is usually 
classified in to two categories: 
a) Essential hypertension, also known as idiopathic or primary hypertension, has no 
identifiable causes and occurs in 95% of cases (Oparil et al., 2003). 
b) Secondary hypertension, has identifiable causes and occurs in less than 10% of cases 
(Czarina Acelajado and Calhoun 2010).  
 
1.2 Complications of hypertension 
Hypertension is one of the major risk factors for cardiovascular and cerebrovascular 
diseases (Whelton, 1994). It occurs in isolation in less than 20% cases and is almost 
always accompanied by other risk factors (Kannel, 2000). By causing electrolyte 
imbalance, hypertension increases contractile responses, proliferation of the smooth 
muscle cells, and results in hypertrophy. This hypertrophy contributes to narrowing of 
the blood vessels and increases the distance required for the diffusion of oxygen from 
the lumen (Alexander, 1995). Thus causes decrease in partial pressure of oxygen (PO2), 
incomplete oxidation, increased free radical concentration, oxidative stress in the arterial 
wall, tissue damage, and leads to micro and macro-vascular complications (Alexander, 
1995). As cardiovascular, cerebrovascular and renovascular systems are involved in 
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blood pressure regulation, so hypertension causes damage to all of them (Oparil et al., 
2003; Beevers et al., 2007). 
 
1.2.1 Hypertension and cardiovascular diseases 
Hypertension is one of the major cause of cardiovascular diseases (Lenfant et al., 2003). 
In population ageing between 40 to 69 years, each increment of 20 mm Hg SBP or 
approximately equivalent 10 mm Hg DBP is associated with twofold increase in  
mortality due to stroke, ischemic heart disease (IHD) and other vascular complications 
(Lewington et al., 2002). The prevalence of congestive heart failure (CHF) was about 
twofold in hypertensive males as compared to normotensive males, and threefold in 
hypertensive females as compared to normotensive females (Levy et al., 1996). In a 
three year follow up study of patients having age more than 65 years, the nonfatal 
cardiovascular events of myocardial infarction (MI), angina pectoris and heart failure 
(HF) were significantly correlated with hypertension (Trenkwalder et al., 1999).  
 
1.2.2 Hypertension and diabetes mellitus 
Diabetes mellitus and hypertension are strongly interrelated with each other. High 
prevalence of diabetes mellitus among hypertensive patients has been reported by 
various studies. In a six-year follow up study, a significant association was found 
between the onset of diabetes mellitus and the presence of hypertension (Weycker et al., 
2009). In a study conducted in Thailand, 78% of diabetic patients were hypertensive 
(Bunnag et al., 2006). Similarly, 67% of diabetic patients were hypertensive in a study 
conducted in Malaysia (Chan, 2005). Both hypertension and diabetes in combination 
alter the endothelial cell structure and function, resulting in vascular complications of 
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atherosclerosis, nephropathy and retinopathy (Hsueh and Anderson, 1992). Diabetic 
patients who are already at greater risk of cardiovascular events, the presence of 
concurrent hypertension results in threefold increase in risk of coronary artery diseases 
(CAD) and twofold increase in  risk of total mortality and stroke (Sowers et al., 2001). 
 
1.2.3 Hypertension and renal disease 
Hypertension; both the cause and consequence of renal disease is an  accelerating factor 
for progression of renal failure (Whitworth, 2005). In Reduction of Endpoints in Non-
insulin dependent diabetes mellitus with the Angiotensin II Antagonist Losartan 
(RENAAL) study, increase in baseline SBP was associated with increase in the risk of 
end stage renal disease (ESRD) or death (Bakris et al., 2003). In Modification of Diet in 
Renal Disease (MDRD) study, lowering DBP <90 mm Hg decreased the rate of  
glomerular filtration rate (GFR) decline (Buckalew, 1996). The survival probability of 
renal function at 10 years decreased with increase in mean  blood pressure (BP) among 
patients with renal disease of different etiologies (Oldrizzi et al., 1993). BP control 
lowers the progression of end stage real failure (ESRF) in patients with non diabetic 
renal disease. Antihypertensive regimens containing Angiotensin converting enzyme 
inhibitors (ACE inhibitors) are more beneficial in halting the progression of renal 
disease and improving the rate of GFR (Marcantoni et al., 2000). 
 
1.2.4 Hypertension and cerebrovascular disease 
Elevated BP disrupts the auto-regulatory mechanism responsible for smooth and 
consistent cerebral blood flow, resulting in damage to cerebral blood vessels, thickening 
of the blood vessel walls, microaneurysmal formation and exposure to stroke (Ogunniyi 
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and Talabi, 2001). In a population based case control study, after adjustment for 
confounding factors, strong correlation was observed between the events of stroke and 
uncontrolled hypertension. Twenty seven percent of the ischemic stroke and 57% of the 
hemorrhagic stroke was attributed to uncontrolled hypertension (Klungel et al., 2000). 
Similarly, the relative risk of stroke was greater in patients with uncontrolled 
hypertension than patients with controlled hypertension (Klungel et al., 1999). In a 
meta-analysis of 61 observational studies it was observed that mortality rate from stroke 
was strongly associated with hypertension (Lewington et al., 2002). Results of clinical 
trials have shown that risk of stroke is clearly reduced by lowering BP (Gueyffier et al., 
1997). 
 
1.3 Prevalence, awareness and control of hypertension 
Hypertension is a prevalent medical condition in both developed and as well as in 
developing countries. Nine hundred and seventy two million people around the world 
were suffering from hypertension in 2000, which is projected to be increase by 60% to a 
total of 1.25 billion in 2025 (Kearney et al., 2005). Despite its high prevalence, the 
majority of hypertensive patients are either unaware of their diseased condition; large 
proportion of the aware population is not on pharmacotherapy and control is suboptimal 
in those who are on pharmacotherapy (Mohan and Campbell, 2009). According to 
National Health and Nutritional Examination Survey (NHANES 1999-2004), 29.6% 
population of the United States suffered from hypertension, and 66.5% of them were 
aware of their diseased state. Only 53.7% of the aware subjects were on 
pharmacotherapy and 63.9% of the treated subjects were on goal BP. The overall control 
rate was 33.1%  (Ong et al., 2007). In Netherlands 21.4% males and 14.9% females of 
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age 30-59 years were hypertensive respectively. Only 17.9% of the hypertensive men 
and 38.5% of the hypertensive women were on antihypertensive medications. According 
to Dutch Hypertension Guidelines, 21.9% of the untreated men and 13.6% of the 
untreated women were eligible for pharmacotherapy (Schelleman et al., 2004).  
 
Hypertension is not a public health problem in the developed world only; the developing 
countries are also suffering to the same extent. Of the 972 million hypertensive subjects 
worldwide in 2000; approximately 669 million were from developing world (Kearney et 
al., 2005). In China, 27.2% of the adult population aged between 35 to 74 years was 
suffering from hypertension. Less than 45% were aware of their diseased condition, 
28.2% of patients were on treatment, and only 8.1% were on goal BP (Gu et al., 2002). 
Third National Health Examination Survey 2004 of Thailand has reported 22% 
prevalence of hypertension in population having age > 15 years. Only 31.2% of the 
hypertensive subjects were aware of their hypertension, 72.8% of the aware patients 
were on pharmacotherapy and only 36.6% of the treated subjects were on goal BP 
(Aekplakorn et al., 2008). 
 
Similarly the prevalence of hypertension in Malaysia in subjects having age > 30 years 
has increased from 32.9% in 1996 to 40.5% in 2004. Only 28.6% of the hypertensive 
patients who were on antihypertensive therapy were on goal BP (Rampal et al, 2008). 
 
1.4 Factors contributing to suboptimal control of hypertension 
According to various guidelines goal BP for uncomplicated and hypertension with 
various comorbidities is given in table 1.1. 
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Table 1.1 Goal BP according various hypertension guidelines 
Guideline Patient assessment Goal BP 
(mm Hg) 
ESC/ESH (2007) Uncomplicated hypertension < 140/90 
Hypertension with comorbidities (Diabetes, 
CKD, Stroke, MI, Proteinuria) 
< 130/80 
JNC 7 (2003) Uncomplicated hypertension < 140/90 
Hypertension with Diabetes &/or CKD < 130/80 
WHO/ISH (2003) Uncomplicated hypertension < 140/90 
Hypertension with Diabetes &/or CKD < 130/80 
CPG (2008) Uncomplicated hypertension < 140/85 
Hypertension with Diabetes &/or CKD < 130/80 
Hypertension with proteinuria > 1 g/24 hrs < 125/75 
CKD, chronic kidney disease; MI, Myocardial infarction CPG: clinical Practice Guidelines, 
ESH/ESC: European Society of Hypertension and European Society of Cardiology; ISH, 
International Society of Hypertension; JNC 7, Seventh Report of Joint National Committee on 
the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; WHO, World 
Health Organization 
 
Large number of studies has been conducted to identify factors contributing to poor 
control of hypertension.  These factors are arbitrarily classified into patients’ related, 
health care providers’ related and system related factors (Borzecki et al., 2005; 
Ogedegbe, 2008; Wofford and Minor, 2009). Most common patients related factors 
include non-adherence to medication, medication side effects, pathophysiological causes, 
age, gender, family history, alcohol intake, knowledge of hypertension, risk factors 
associated, psychosocial stress etcetera (Borzecki et al., 2005; Ogedegbe, 2008). 
 
Health care provider related factors include clinical inertia, doctors attitudes towards 
hypertension management, overestimation of the treatment provided, failure to motivate 
patients to participate in achieving BP goal and constraints of time (Borzecki et al., 2005; 
Ogedegbe, 2008). System related factors include lack of access to the health care, patient 
provider interaction and practice setting (Borzecki et al., 2005; Ogedegbe, 2008). 
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The need to improve hypertension control has initiated the development and 
dissemination of hypertension management guidelines with the aim to assist health care 
professionals (Lenfant et al., 2003; Whitworth, 2003).  
 
1.5 Clinical Practice Guidelines 
Clinical quality is achieved by developing a system that enhances and optimizes access, 
multidisciplinary approach, implementation of best practices and patient participation in 
clinical decision making. Dramatic practice variation observed in clinical practice 
regarding diagnosis, treatment and prevention of a disease due to uncertainty, biases, and 
differences of opinions, motives, and values affects clinical quality (Eddy, 1984). In 
order to change the clinical practice and line up it with evidence based medicine (EBM), 
multiple strategies including management, regulation and education have been implied 
(Browman et al., 1995; Woolf et al., 1999). Clinical  Practice Guidelines  (CPG), 
defined as “systematically developed statements to assist practitioner and patient 
decisions about appropriate health care for specific clinical circumstances” (Field and 
Lohr, 1990) imply all these strategies, and are one the several mechanisms for improving 
clinical quality (Woolf, 1990). 
 
The objective of CPG is to achieve effective and efficient patient care, educate 
practitioners, patients and their families, assure and assess quality of care, and guide 
allocation of health care resources (Tan, 2006). Properly developed guidelines bring  
EBM into practice; reduce irrational practices, harmful interventions, and make sure the 
best  possible outcomes at the reduced cost (Culleton, 2009). 
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The delay in implementation of research findings in clinical practice results in 
suboptimal care of patients. The extreme example of such delay is the use lemon juice 
for the prevention of Scurvy, which took 50 years for British Navy and 120 years for 
Merchant Marine to practice it after the discovery (Haines and Jones, 1994). It is found 
that on average it takes 17 years to integrate the facts found in a clinical trial into clinical 
practice, and even then the evidence is not incorporated in systematic way (Carroll 
2002). The effective and systematic way of bringing and practicing these evidences in to 
clinical practice is the development and dissemination of CPG (Grimshaw et al., 2005). 
 
Clinical practice guidelines which were initially mainly based on expert opinions of 
“opinion leaders” are now considered to be evidence based and systematically developed 
(Lohr et al., 1998). Clinical practice guidelines should be valid, reliable, clinically 
applicable and flexible, explicit, developed through multidisciplinary process, 
continuously updated  and documented (Field and Lohr, 1990; Tan, 2006). The skills 
and resources required for the development of CPG are usually not available to 
individuals or a single health care organization, due to this reason CPG are developed by 
specialized national and international institutions (OllenschlÃger et al., 2004). 
 
1.5.1 Impact of Clinical Practice guidelines on patient outcomes 
Large number of CPG are developed, widely disseminated and regularly updated in 
almost every field of medicine including both physical and mental health. For improving 
the delivery of quality of care to achieve best possible outcomes, the systematic 
dissemination and successful implementation of the guidelines is of utmost importance 
(Lugtenberg et al., 2009).  
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Existing literature suggests that most of the time successful implementation of 
guidelines has resulted in improved quality of care and patient outcomes. For example, 
successful implementation of the guidelines developed by Dutch College of General 
Practitioners on the management of asthma and chronic obstructive pulmonary disease 
(COPD) resulted in significant improvements in lung functions and respiratory 
symptoms (Jans et al., 2001). In a multi-centre observational study conducted in six 
European countries France, Germany, The Netherlands, Italy, Spain and UK, adherence 
to the European guidelines on management of CHF was strongly and independently 
correlated with fewer CHF and cardiovascular hospitalization rates (Komajda et al., 
2005). Hypertension control was significantly better in high risk cardiovascular patients 
treated by group of physicians who had received specific training European Society of 
Hypertension (ESH) guidelines (Asmar et al., 2007). Ansari et al., 2003 while 
conducting a retrospective cohort study on new onset heart failure (HF) outpatients 
found that adherence to guidelines was the only predictor of reduction in mortality and 
cardiovascular hospitalization. 
 
In Implementation of guidelines for the management of arterial hypertension 
(IMPULSION) study, a notable improvement was seen in achieving BP goal 
(Karagiannis et al., 2009). Positive outcomes of CPG implementation on the control of 
hypertension was seen in a study conducted at Kyushu University Hospital (Ohta et al., 
2004). Similar promising results regarding improvement in quality of care and control of 
hypertension were observed after the implementation Local Clinical Practice Guidelines 
for Hypertension (LCPGH) in a study conducted in Kuwait (Al-Awadhi et al., 2007).  
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Findings of these studies suggest that guidelines have the potential to improve quality of 
care and achieve best possible patient outcomes. 
 
1.5.2 Clinical practice guidelines and management of hypertension in clinical 
practice 
In order to improve hypertension control, reduce practice variation and provide cost 
beneficial therapy a large number of guidelines for the management of hypertension has 
been developed and disseminated in various countries around the world. Various major 
guidelines for management of hypertension include World Health 
Organization/International Society of Hypertension Guidelines on Management of 
Hypertension (WHO/ISH 2003), Guidelines for the Management of Arterial 
Hypertension of the European Society of Hypertension and the European Society of 
Cardiology (ESH/ESC 2007), Seventh report of the Joint National Committee on 
prevention, detection, evaluation, and treatment of high blood pressure (JNC 7) , British 
Society of Hypertension Guidelines (BSH 2004) and Canadian Hypertension Education 
Program (CHEP 2009). Ministry of health Malaysia in collaboration with, Malaysian 
Society of Hypertension and Academy of Medicine is also developing and disseminating 
guidelines for the management of hypertension since 1998. The latest version of 
Malaysian clinical practice guideline on management of hypertension CPG (2008) is 
issued in 2008. 
 
Despite the availability and dissemination of hypertension management guidelines, 
literature review suggests the existence of a wide gap between guidelines recommended 
and actual clinical practices. While managing hypertension, almost the same problems 
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and deviation from the guidelines recommended practices are observed in each country, 
namely, insufficient diagnostic work (Cuspidi et al., 2002; Spranger et al., 2004; Marija 
et al., 2007) setting a high threshold BP levels than recommended (Berlowitz et al., 
1998; Oliveria et al., 2002; Jafar et al., 2005; Redón et al., 2010), poor evaluation and 
recording of cardiovascular risk factors (Langham et al., 2002; Sheerin et al., 2007), 
insufficient patient counseling on non pharmacological interventions (Hobbs and Erhardt, 
2002; Odili et al., 2008), and prescription of antihypertensive agents other than 
recommended (Monane, et al., 1995; Siegel and Lopez, 1997; Knight et al., 2000; Chan, 
2005; Drawz et al., 2009; Ramli et al., 2010). 
 
Pharmacotherapy is one of the main stay of hypertension management. On the basis of 
evidences obtained from clinical trials, guidelines have recommended various 
antihypertensive classes as preferred agents for treating hypertension with and without 
compelling indications. Initial choice of therapy recommended by various hypertension 
guidelines in various conditions is given in table 1.2 
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Table 1.2 Preferred antihypertensive agents by various guidelines in patients with and without compelling indications 
Guideline Patient assessment Initial Drug choices 
JNC 7 No compelling indication Thiazide Diuretics (for most patients) 
Diabetes mellitus  ACEI, ARB 
Chronic kidney disease  ACEI , ARB 
Stable angina pectoris BB (for most) alternatively CCB can be used 
Unstable angina or myocardial infarction BB, ACEI 
 Post myocardial infarction ACEI, BB, Aldosterone Antagonists 
Asymptomatic heart failure with 
demonstrable ventricular dysfunction 
ACEI, BB 
Heart failure with symptomatic Ventricular 
dysfunction or end stage heart disease 
ACEI, BB, ARB, Aldosterone Antagonists along 
with Loop diuretics 
WHO/ISH guidelines 
(2003) 
 No compelling indication Thiazide diuretics (for most patients) 
Diabetic nephropathy type 1 ACEI 
Diabetic nephropathy type 2 ARB 
Non diabetic nephropathy ACEI 
Post myocardial infarction ACEI, BB 
Left ventricular dysfunction ACEI 
Congestive heart failure 
 
Diuretics almost always included, BB, 
Spironolactone 
Left ventricular hypertrophy ARB 
Cerebrovascular disease ACEI, Diuretic 











“Table 1.2 continued” 
Malaysian CPG (2008) 
 
No compelling indication ACEI,ARB,CCB,Diuretics 
Diabetes mellitus without proteinuria ACEI 
Diabetes mellitus with proteinuria ACEI, ARB 
Chronic kidney disease ACEI 
Coronary heart disease BB, ACEI, long Acting CCB 
Coronary heart disease  with post 
myocardial infarction  and/or left 
ventricular dysfunction 
BB, ACEI, Aldosterone antagonists 
 
 
Heart failure Diuretics, ACEI, BB, ARB, Aldosterone antagonists 
Left ventricular hypertrophy ARB 
Primary prevention of Stroke CCB 
Secondary prevention of stroke ACEI, ARB 
Elderly with isolated systolic hypertension Diuretics 
ACEI, Angiotensin converting enzyme inhibitor; ARB, Angiotensin receptor blocker; BB, Beta blockers; CCB, Calcium channel 
blockers; CPG, Clinical practice guidelines; ISH, International Society of Hypertension; JNC 7, Seventh Report of Joint National 




Despite evidence based pharmacotherapeutic recommendations, doctors are found to 
deviate from guidelines while prescribing antihypertensive drugs. For example, in a 
study conducted at a nursing home in United States of America (USA), only 18% of 
uncomplicated hypertensive patients received JNC 7 recommended therapy. The 
majority of patients to whom Thiazide diuretics should have been prescribed were on 
BB, ACE inhibitors, CCB and ARB (Drawz et al., 2009). Guidelines divergent 
antihypertensive prescribing trend was observed in a study conducted in Taiwan. More 
than half of the patients were on monotherapy. Among all of the monotherapy, CCB 
were the highly prescribed drugs, prescribed to 33.5% patients, followed by BB. 
guidelines recommended diuretics made only 8.3% of the whole monotherapy  (Pang-
Hsiang and Jung-Der, 2008). Similarly only 50% of the essential hypertensive patients 
were on the JNC 6 recommended diuretics and BB, and 51.3% of the diabetic 
hypertensive patients were on diuretics and CCB rather than the JNC 6 recommended 
ACE inhibitors (Holmes et al., 2004). In a study conducted in USA, CCB and ACE 
inhibitors were the most commonly prescribed antihypertensives to elderly patients 
rather than guidelines recommended Thiazide diuretics and BB (Knight et al., 2000). 
Similar findings were observed in another study conducted in USA, which concluded 
that the antihypertensive prescribing practices from 1992 to 1995 were not in accordance 
with JNC V guidelines, where decrease in prescription of guidelines recommended 
Thiazide diuretics and BB was observed (Siegel and Lopez, 1997). 
 
Similar scare and poor adherence to hypertension guidelines was observed in studies 
conducted in Malaysia. A cross sectional study conducted at 11 health care clinics in 
Melakah has reported that only 3.1% of the diabetic hypertensive patients were on goal 
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BP.  One hundred and thirty four of the uncontrolled hypertensive patients were not on 
antihypertensive therapy and only 18.3% of the diabetic hypertensive patients were on 
the CPG (2002) recommended ACE inhibitors (Chan, 2005). Due to accumulating 
evidence that the use of BB is associated with significant increase in stroke (Lindholm et 
al., 2005) and cardiovascular events in elderly patients (Khan and McAlister, 2006), 
Malaysian CPG (2008) has discouraged the use of BB as initial agents for treating 
uncomplicated hypertension. Despite the discouragement by CPG (2008), BB were 
reported the most commonly prescribed drug in the form of mono as well as 
combination therapy in a study conducted in Malaysia (Ramli et al., 2010).  
 
1.6 Adherence to clinical practice guidelines 
The findings of abovementioned studies indicate the existence of a large discrepancy 
between the guidelines recommendations and management of hypertension in clinical 
practice. There are several models which discuss the process and factors leading to 
guidelines adherence.  
 
1.6.1 Awareness to Adherence Model 
Implementation of guidelines in clinical practice is not a straight forward process. 
Various strategies are adopted for its implantation. These strategies include diffusion, 
dissemination and implementation. After concluding that Passive Dissemination Model 
(a model based on assumption that targeted audience specific communication of the 
guidelines will affect and change their behavior) is over-simplistic, Pathman and his 
colleagues proposed a model known as Awareness to Adherence Model to explain the 
process resulting in adherence to guidelines (Pathman et al., 1996).  
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Pathman model is a phase model consisting of four steps that is awareness, agreement, 
adoption and adherence. According to the model, for performing a behavior or adhering 
with a practice, first of all it is necessary to become aware of the practice (awareness), 
then agree with it (agreement), then decide to follow it (adoption) and at last following it 
in the practice successfully (adherence) (Pathman et al., 1996). This model is based on 
Trans-theoretical Model of change, which consists of five stages, pre-contemplation, 
contemplation, action, maintenance and relapse. According to Trans-theoretical model 
the individual takes change intentionally after becoming aware of the pros of change and 
cons of  former behavior (Prochaska and DiClemente, 1983).  
 
Although the study conducted by Pathman et al., 1996 supported his model, but still 
11%  doctors adhered with Hepatitis B vaccine’s recommendation without being agree 
with it. Support for Awareness to Adherence model is reported by a study conducted in 
UK. The model was evaluated for recommendations of British Hypertension Society 
(BHS) and National Institute of Health and Clinical Excellence (NICE) guidelines. It 
was observed that model was not applicable only to 6-8% of the doctors’ responses, but 
a larger discrepancy of 15% to 19% was observed for the recommendations for which 
respondents were receiving financial incentives. The doctors reported adherence to 
guidelines recommended practices without being expressing awareness or agreement 
(Heneghan et al., 2007). In another study it is found that although awareness, agreement 
and adoption were the strongest predictors of adherence to guidelines recommendations, 
the adoption rate varied even among the doctors who were familiar with the 
recommendations. Thus suggesting practical obstacles other than awareness to the 
implementations of guidelines (Beaulieu et al., 2005). 
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1.6.2 Cabana Model 
An alternative model of guidelines adherence is proposed by Cabana and his colleagues 
(Cabana et al., 1999). After conducting a review of 76 studies, examining barriers to 
guidelines adherence, they found that factors related to knowledge, attitude and behavior 
act as barriers to guidelines adherence. According to the model, barriers limiting 
adherence to guidelines are classified into three categories: 
 
1.6.2 (a) Knowledge related factors 
 These include factors which limit guidelines adherence through cognitive
 components such as lack of awareness and familiarity.  
1.6.2 (b) Attitude related factors  
These include factors which limit guidelines adherence through affective 
component such as lack of agreement, lack of outcome expectancy, self efficacy 
and motivation. 
1.6.2    (c ) Behavior related factors 
These include factors which limit guidelines adherence by restricting doctors’  
ability such as characteristics of patients, guidelines and practice. 
 
This model suggests a sequential process of behavior change, that is, guidelines first 
affect doctors’ knowledge, then attitude before changing their behavior. Although 
behavior can be changed without changing knowledge and attitude but that change is not 




1.7 Factors affecting guidelines adherence 
 
1.7.1 Doctors’ knowledge or familiarity with guidelines 
Doctors’ adherence to guidelines is repeatedly linked to their familiarity with guidelines, 
which is considered to be the first step to implement them in clinical practice (Pathman 
et al., 1996; Cabana et al., 1999; Windak et al., 2007). It is found that doctors who were 
more familiar with the guidelines remained more adhere to them (Cheng et al., 1996; 
Hyman and Pavlik, 2000; Nelson et al. 2003; Ikeda et al. 2005; Petek Šter and Kersnik, 
2005; El-Solh et al., 2010). 
 
However this relationship between doctors’ knowledge and adherence to guidelines does 
not necessarily follow the same sequence always. For example in a study only, 51.8% 
doctors were using guidelines occasionally or always, despite the fact that all of them 
were well aware of guidelines’ recommendations (Wang and Wang, 2004). Similar poor 
adherence to JNC 7 guidelines was noted among doctors 94% of whom were familiar 
with its recommendations (Holland et al., 2008). 
 
1.7.2 Doctors attitudes toward guidelines 
Attitudes refer to feelings as well as preconceived ideas towards a particular subject 
(Kaliyaperumal, 2004). Doctors’ attitudes towards guidelines play a significant role in  
their implementation in clinical practice (Cabana et al., 1999). Doctors’ intentions to use 
the guidelines can be predicted from their attitudes towards them (Limbert and Lamb, 
2002) which are influenced by many factors, such as their knowledge, past clinical 
experience, beliefs about guidelines, outcome expectations, peers’ opinions and 
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guidelines characteristics (Tan, 2006). Doctors’ positive attitudes towards guidelines 
were associated with adherence to guidelines and vice versa. (Merritt et al., 1999; 
Subramanian, et al. 2004; Beaulieu et al., 2005; Haagen et al., 2005; Quiros et al., 2007). 
 
1.7.3 Doctors demographics  
Beside knowledge and attitudes, doctors demographics were also been tied to guidelines 
adherence. Doctors’ age (Nelson et al., 2003; Holmes et al., 2004; Ikeda et al., 2005), 
gender (Nichol and Zimmerman, 2001; Broder et al. 2005; Skelding et al., 2006), 
specialty and experience (McAlister et al., 1997; Fams et al., 2002; Cuspidi et al., 2003; 
Schaars et al., 2004)  were also reported to had association with guidelines adherence. 
 
1.7.4 Practice setting characteristics 
According to Cabana et al., 1999 in addition to knowledge and attitudes other contextual 
variables like implementation strategy, practice characteristics, opinion leaders, and 
audit of the practices also affect adherence to guidelines. For example placing written, 
verbal and computer based reminder tools at practice setting increased guidelines 
adherence (Weingarten et al., 1994; Goethe et al., 1997). In a qualitative study the 
respondents cited structural barriers like work load, lack of ready access to protocols, 
inadequate computerization and lack of audit on practices as reasons for nonadherence 
to hypertension guidelines (Cranney et al., 2001). Similarly, lack of appropriate 
supportive staff, financial constraints, work and information overload, lack of training 
and audit of physicians’ practices, and influence of local consultants were contributing 
factors for non adherence to  guidelines (Hobbs and Erhardt, 2002; Rashidian et al., 
2008).  
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1.7.5 Patients’ factors 
In addition to doctors and system related factors, some studies have found relationship 
between doctors’ adherence to guidelines and patients’ factors like age, gender, ethnicity, 
insurance status, comorbidities etcetera.  Studies have reported mixed results in this 
regard. In a study it is observed that male gender was associated with receiving 
guidelines recommended antihyperlipidimic drugs in patients at high risk for 
cardiovascular diseases (Graversen et al., 2010). In another study female gender was 
found to be associated with receiving guidelines recommended therapy as compared to 
male patients (Holmes et al., 2004; Skelding et al., 2006). Guidelines recommended 
hypertension management was significantly associated with patients minority status (non 
white), total comorbidities, CAD, history of myocardial infarction, history of stroke, 
diabetes and number of medications (Ardery et al., 2007). Some studies had not found 
any relationships between the patients’ characteristics and doctors’ adherence to 
guidelines (Russell et al., 2005; Wae et al., 2006). 
 
1.8 Conceptual Frame work 
The above discussion regarding poor control of hypertension can be simply summed up 
in Fig 1.1 
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Fig 1.1 Factors contributing to poor control of hypertension 
 
1.9 Measuring adherence to hypertension guidelines 
 
Various strategies are used to evaluate doctors’ adherence to hypertension guidelines. 
These strategies include: 
i. Antihypertensive prescription data and prescribing trends over the time 
ii. Survey conducted via a questionnaire 
iii. Revision of patients’ medical record 
Poor hypertension 
control 
Patient factors Medical environment factors 
Doctors lack of adherence to 
guidelines 
Knowledge Attitude Behavior 
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1.9.1 Evaluation of guidelines adherence by utilizing prescription data and 
prescribing trends over the time 
Using prescription data and prescribing trends over the time is one of the main strategies 
used for evaluating doctors’ adherence to hypertension guidelines. Different conclusions 
have been drawn by these studies. Basic features of the studies which had used this 








Table 1.3 Basic features of the studies which has evaluated guidelines adherence by evaluating prescription data and 








Related adherence to 
hypertension control 
Conclusion  
(Monane et al., 1995) No No No Prescribing practices were 
not in line with guidelines 
(Siegel and Lopez, 
1997) 
No No No Prescribing practices were 
not in line with guidelines 
(Nelson and Knapp, 
2000) 
No No No Prescribing practices were in 
line with guidelines 
(Knight et al., 2000) Yes No No Prescribing practices were 
not in line with guidelines 
(Siegel et al., 2001) No No No Prescribing practices were 
not in line with guidelines 
(Campbell et al., 
2003) 
No No No Prescribing practices were in 
line with guidelines 
(Hemmelgarn et al., 
2008) 
No No No Prescribing practices were in 
line with guidelines 
(Pang-Hsiang and 
Jung-Der, 2008) 
Excluded No No Prescribing practices were 
not in line with guidelines 
(Drawz et al., 2009) Excluded Yes No Prescribing practices were 
not in line with guidelines 
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1.9.1 (a) Limitations 
i)    Except the studies conducted by Knight et al., 2000 and (Pang-Hsiang and 
Jung-Der, 2008;  Drawz et al., 2009) in which comorbidities were included 
and excluded respectively, none of the above studies have addressed 
comorbidities, an important consideration while evaluating guidelines 
adherence (Carter et al., 2000). 
ii)   The majority studies have not defined explicit criteria for guidelines 
adherence. 
iii)    Except the study conducted by Drawz et al., 2009, rest of them failed to 
conduct the detailed review of patients’ medical record to find whether the 
divergence from guidelines was justifiable or not. 
iv)    None of the above studies correlated practices to hypertension control, this 
limitation made these studies somewhat non conclusive. 
 
1.9.2 Evaluation of guidelines adherence by using doctors’ survey data 
Survey data have been used by various researchers to evaluate doctors’ familiarity with 
hypertension guidelines. These studies were based on the hypothesis that doctors’ poor 
familiarity about hypertension guidelines is a major reason for guidelines divergent 
practices. Different conclusions have been drawn by these studies. Basic features of 
these studies are given in table 1.4. 
 
